Wells Fargo Maintains Overweight on Metagenomi Therapeutics, Lowers Price Target to $7

Benzinga Newsdesk www.benzinga.com Negative 90.4%

Neg 90.4% Neu 0% Pos 0%

Wells Fargo analyst Yanan Zhu maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Overweight and lowers the price target from $9 to $7.